Payment overview · 2025
General Payments
$628.24
34 reported records · 12 companies
Healthcare provider profile · identity verified
Frank Savoretti, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSTON, RI · NPI 1750377149
Verified facts
What the public records show
CMS Open Payments records show Frank Savoretti, MD received $628.24 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.50 | 25.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $156.50 | 24.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.63 | 8.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.45 | 8.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.72 | 7.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $37.85 | 6.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.00 | 5.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.47 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.96 | 2.9% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.11 | 2.4% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $13.52 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $628.24 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $159.50 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $142.59 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $111.08 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $92.32 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 34 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 192 |
| Alprazolam | Alprazolam | 556 | 100 |
| Omeprazole | Omeprazole | 548 | 175 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 373 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 362 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 94 |
| Metformin Hcl | Metformin Hcl | 305 | 89 |
| Prednisone | Prednisone | 304 | 207 |
| Lisinopril | Lisinopril | 295 | 86 |
| Simvastatin | Simvastatin | 218 | 61 |
| Losartan Potassium | Losartan Potassium | 190 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 76 |
| Famotidine | Famotidine | 181 | 55 |
| Montelukast Sodium | Montelukast Sodium | 181 | 62 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 177 | 144 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 55 |
| Atenolol | Atenolol | 169 | 50 |
| Clonazepam | Clonazepam | 165 | 36 |
| Meloxicam | Meloxicam | 161 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 43 |
| Sertraline Hcl | Sertraline Hcl | 137 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 64 |
| Furosemide | Furosemide | 126 | 44 |
| Lovastatin | Lovastatin | 125 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 34 |
| Trazodone Hcl | Trazodone Hcl | 116 | 45 |
| Eliquis | Apixaban | 105 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 33 |
| Gabapentin | Gabapentin | 93 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 92 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 30 |
| Glimepiride | Glimepiride | 88 | 26 |
| Finasteride | Finasteride | 73 | 22 |
| Azithromycin | Azithromycin | 72 | 59 |
| Diazepam | Diazepam | 68 | 12 |
| Ibuprofen | Ibuprofen | 66 | 16 |
| Mirtazapine | Mirtazapine | 64 | 19 |
| Allopurinol | Allopurinol | 63 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 61 | 23 |
| Lorazepam | Lorazepam | 60 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 21 |
| Potassium Chloride | Potassium Chloride | 56 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 50 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 40 | 11 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Spironolactone | Spironolactone | 39 | 13 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Temazepam | Temazepam | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 22 | 19 |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Nystatin | Nystatin | 19 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $628.24 · 34 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, INSPIRE, JARDIANCE, OPSUMIT, OTEZLA, PAXLOVID, REPATHA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, UPTRAVI, ZURZUVAE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Paxlovid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error